Invivyd finishes late-stage enrollment for upsized covid antibody study
Share
Invivyd (NASDAQ:IVVD) completed enrollment for the pivotal Phase 3 clinical trial of its leading monoclonal antibody candidate, positioning the biotechnology firm to deliver late-stage results later this quarter.
